PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS-19, COMPRISING CAS13 PROTEIN AND CRRNA

The present invention relates to a pharmaceutical composition for preventing or treating coronavirus-19, comprising Cas13 proteins and crRNA. Particularly, Cas13b and scRNA, which targets the RdRp gene region of ORF1b of SARS-CoV-2, of the present invention, are not cytotoxic and have the excellent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YU, Daseuli, HEO, Won Do, YU, Jeonghye
Format:	Patent
Sprache:	eng ; fre ; kor
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a pharmaceutical composition for preventing or treating coronavirus-19, comprising Cas13 proteins and crRNA. Particularly, Cas13b and scRNA, which targets the RdRp gene region of ORF1b of SARS-CoV-2, of the present invention, are not cytotoxic and have the excellent ability to degrade SARS-CoV-2 RNA, and thus can be effectively used as therapeutic agents for coronavirus disease 19. La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement du coronavirus-19, comprenant des protéines Cas13 et de l'ARNcr. En particulier, Cas13b et ARNsc, qui cible la région du gène RdRp d'ORF1b du SARS-CoV-2, de la présente invention, ne sont pas cytotoxiques et ont une excellente capacité à dégrader l'ARN du SARS-CoV-2, et peuvent ainsi être utilisés efficacement en tant qu'agents thérapeutiques pour la maladie du coronavirus 19. 본 발명은 Cas13 단백질 및 crRNA를 포함하는 코로나바이러스감염증-19 예방 또는 치료용 약학적 조성물에 관한 것으로, 구체적으로 본 발명의 Cas13b 및 SARS-CoV-2의 ORF1b의 RdRp 유전자 부분을 표적으로 하는 scRNA는 세포 독성이 없고, SARS-CoV-2의 RNA를 분해하는 능력이 우수하므로 코로나바이러스감염증-19의 치료제로 유용하게 사용될 수 있다.